πŸ‡ΊπŸ‡Έ FDA
Patent

US 10358487

Anti-ANGPTL3 antibodies and uses thereof

granted A61KA61K2039/505A61K31/455

Quick answer

US patent 10358487 (Anti-ANGPTL3 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K31/455, A61K39/3955, A61K45/06